PASG News and Press, Passage Bio Inc. From 05/11/23

2023-05-11 10:01:00 ET Passage Bio press release ( NASDAQ: PASG ): Q1 GAAP EPS of -$0.63 misses by $0.13 . Cash, cash equivalents and marketable securities were $167.8 million as of March 31, 2023, as compared to $267.1 million as of March 31, 2022. The Company expects...

On track to report interim clinical data for two lead programs, PBGM01 for GM1 gangliosidosis and PBFT02 for frontotemporal dementia (FTD), in 2023 Submitted protocol amendment to regulatory authorities for Imagine-1 study for GM1 gangliosidosis to treat patients at a third, higher ...

PHILADELPHIA, May 04, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, has announced Nicolette “Nikki” Evich, a sophomore at The Schre...

2023-04-21 15:00:36 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar ...

PHILADELPHIA, April 17, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, and Alex F...

PHILADELPHIA, March 27, 2023 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that William Chou, M.D., chief executive officer, will parti...

2023-03-06 13:07:06 ET Passage Bio, Inc. (PASG) Q4 2022 Earnings Conference Call March 06, 2023 08:30 AM ET Company Participants Stuart Henderson - Vice President, Corporate Development & Investor Relations Will Chou - Chief Executive Officer Mark Forman - Ch...

2023-03-06 12:33:52 ET The following slide deck was published by Passage Bio, Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Passage Bio, Inc. 2022 Q4 - Results - Earnings Call Presentation

2023-03-06 07:05:01 ET Passage Bio press release ( NASDAQ: PASG ): Q4 GAAP EPS of -$0.50 beats by $0.02 . Cash, cash equivalents and marketable securities were $189.6 million as of December 31, 2022, as compared to $315.8 million as of December 31, 2021. The Company ex...

Presented additional interim data at 19 th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023 Planned ex...